https://www.selleckchem.com/products/sr59230a.html
There is significant interest in formulating antibody therapeutics as concentrated liquid solutions, but early identification of developable antibodies with optimal manufacturability, stability, and delivery attributes remains challenging. Traditional methods of identifying developable mAbs with low self-association in common antibody formulations require relatively concentrated protein solutions (1 mg/mL), and this single challenge has frustrated early-stage and large-scale identification of antibody candidates with drug-like coll